Clinical trials: Hepatobiliary Disorders
Type2 Diabetes, NASH - Nonalcoholic Steatohepatitis
A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH
This is a randomized, double-blind study of MSDC-0602K or placebo in subjects with pre-T2D or T2D and evidence of NAFLD/NASH.
- Conditions
- Type2 Diabetes, NASH - Nonalcoholic Steatohepatitis, Nonalcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT03970031
- Testing
- MSDC-0602K
- Volunteers
- 1,800 people
- Sponsor
- Cirius Therapeutics, Inc.
ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
The purpose of this study is to evaluate the safety and tolerability of single or multiple doses of ALN-AAT02. The study will be conducted in 2 sequential phases in which Part A will be a single-ascending dose (SAD) phase in…
- Trial name
- NCT03767829
- Testing
- ALN-AAT02
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Non-alcoholic Steatohepatitis (NASH)
A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects
This is a first-in-human (FIH) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of AZD4076 tetracosasodium in healthy male subjects at increasing single doses
- Trial name
- NCT02612662
- Testing
- AZD4076
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Non-alcoholic Steatohepatitis
Investigate Safety, Tolerability, PK/PD of J2H-1702 in Healthy Females
Objectives: Primary objective_To evaluate the safety and tolerability after single oral administration of the investigational product (IP), J2H-1702 in healthy female subjects.
- Trial name
- NCT06308874
- Testing
- Amg dose administration group, Bmg dose administration group
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- J2H Biotech
Healthy, NAFLD
DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.
The primary objective of this study is to evaluate the effect of itraconazole, a strong inhibitor)of cytochrome P4503A , and phenytoin a strong inducer of cytochrome P450 3A, CYP3A4, CYP1A2 and CYP2C19 on the pharmacokinetics of…
- Trial name
- NCT04845646
- Testing
- ASC41, Itraconazole, Phenytoin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepatitis (NASH).
- Conditions
- Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
- Trial name
- NCT05979779
- Testing
- HU6
- Where
- 20 sites in United States
- Volunteers
- 219 people
- Sponsor
- Rivus Pharmaceuticals, Inc.
Non-Alcoholic Fatty Liver Disease (NAFLD)
Proliverenol Supplementation for Non-Alcoholic Fatty Liver Disease (NAFLD)
This is a 4-arm, prospective, randomized, double-blind, double-dummy, and placebo-controlled clinical study comparing Proliverenol at a dose of 500 mg twice daily; Proliverenol at a dose of 1000 mg once daily; Proliverenol at a…
- Trial name
- NCT06127225
- Testing
- Proliverenol
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- Dexa Medica Group
Non-alcoholic Fatty Liver Disease, Obesity
A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease
This study is open to adults with overweight or obesity who also have fatty liver disease. The purpose of this study is to find the highest dose of BI 3006337 that people with overweight or obesity and with fatty liver disease…
- Trial name
- NCT05970640
- Testing
- BI 3006337
- Where
- 12 sites in United States
- Volunteers
- 64 people
- Sponsor
- Boehringer Ingelheim
Nonalcoholic Steatohepatitis
Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis
This is a multi-center, randomized, placebo-controlled, double-blind, dose-selection, multiple dose administration study comprising three groups, with up to 40 patients in each active treatment and placebo group.
- Trial name
- NCT01466894
- Testing
- IMM 124-E
- Sponsor
- Immuron Ltd.
Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver
This randomized clinical trial aims to compare the effect of the pioglitazone and SGLT2 inhibitor combination on liver fat mass, as compared to either drug used alone, with or without background medical therapy of metformin…
- Conditions
- Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis, NAFLD
- Trial name
- NCT04976283
- Testing
- Pioglitazone, Empagliflozin, Pioglitazone + Empagliflozin
- Where
- Pakistan
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Getz Pharma
Liver Inflammation, Fatty Liver Disease
LivQ-box® Parameters in the Diagnosis of Liver Inflammation
To evaluate the correlation between LivQ-box® parameters carried by iLivTouch and liver inflammation in patients with NAFLD, as well as the diagnostic value of liver inflammation of different severity levels.
- Trial name
- NCT06802731
- Where
- China
- Volunteers
- 365 people
- Sponsor
- Wuxi Hisky Medical Technology Co Ltd
Ulcerative Colitis, Crohn Disease
Systems Biology of Gastrointestinal and Related Diseases
This is a longitudinal observational study on patients with gastrointestinal and related disease. The study will be conducted for at least 10 years, following each participant over time, as they either go through relapses and…
- Conditions
- Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp
- Trial name
- NCT05579444
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Viome
Non-alcoholic Steatohepatitis (NASH)
A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function
Novo Nordisk is developing the study medicine NNC0194-0499 for the treatment of non-alcoholic steatohepatitis (NASH). NASH is a serious disease where fat, inflammation and scar tissue builds up in the liver.
- Trial name
- NCT05727644
- Testing
- NNC0194-0499
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Novo Nordisk A/S
Non-alcoholic Steatohepatitis, Chronic Liver Disease
Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures
The purpose of this study is to assess the ability of eltrombopag to elevate platelet counts thereby reducing the need for platelet transfusions in chronic liver disease patients with thrombocytopenia undergoing elective invasive…
- Conditions
- Non-alcoholic Steatohepatitis, Chronic Liver Disease, HCV, NASH - Nonalcoholic Steatohepatitis
- Trial name
- ELEVATE (NCT00678587)
- Testing
- Eltrombopag
- Where
- 107 sites in United States, Argentina and 11 more
- Volunteers
- 292 people
- Sponsor
- GlaxoSmithKline
NASH - Nonalcoholic Steatohepatitis, Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EYP001a in Healthy Volunteers and Nonalcoholic Steatohepatitis Patients
This is a single centre, open label, randomized, 3 treatment arms, with and without food dosing, Phase 1b pharmacology study to assess the safety, tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Farnesoid X…
- Trial name
- NCT03976687
- Testing
- EYP001a
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Enyo Pharma
Steatotic Liver Disease
German SLD-Registry (Deutsches SLD-Register)
Characterization of patients with steatotic liver disease (SLD) The German SLD-Registry (Deutsches SLD-Register) a project of the German Liver Foundation (Deutsche Leberstiftung), managed by Leberstiftungs-GmbH Deutschland.
- Trial name
- NCT04721665
- Where
- 14 sites in Germany
- Volunteers
- 1,681 people
- Sponsor
- Leberstiftungs-GmbH Deutschland
Healthy, Fatty Liver
Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease
A generic screening study to establish structural and/or functional baselines of specific organs.
- Conditions
- Healthy, Fatty Liver, MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- MASLD (NCT04873258)
- Testing
- Bioimpedence Vector Analysis
- Where
- United Kingdom
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Richmond Research Institute
Chronic Liver Disease
Study to Evaluate Efficacy and Safety of PENNEL Capsule in the Patients With Chronic Liver Disease
The drug in this study is combined product of biphenyl dimethyl dicarboxylate (DDB) and garlic oil. This components showed synergistic enhancing effects in previous tests.
- Trial name
- NCT01393678
- Testing
- NISSEL, PENNEL
- Where
- South Korea
- Volunteers
- 220 people
- Sponsor
- PharmaKing
Nonalcoholic Steatohepatitis (NASH)
A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
An Open-Label Part was added: This part will enroll in selected sites which are less affected by the COVID-19 pandemic. 150 subjects with NASH and fibrosis confirmed by liver histology (F1-F3) will be randomized into 3 groups…
- Trial name
- ARMOR (NCT04104321)
- Testing
- Aramchol free acid
- Where
- 2 sites in United States
- Volunteers
- 157 people
- Sponsor
- Galmed Research and Development, Ltd.
Overweight and Obesity, Cardiovascular Diseases
Study Consortium for Evaluation of RNPC Program in Obese and Overweight Patients (SCOOP-RNPC)
The investigators hypothesize that weight loss obtained with the French RNPC weight reduction program is beneficial for the general health of overweight/obese patients in the medium term.
- Conditions
- Overweight and Obesity, Cardiovascular Diseases, Metabolic Disease, Diabete Type 2
- Trial name
- SCOOP-RNPC (NCT05857319)
- Testing
- Nutritional Psycho-Behavioral Reeducation Program
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Groupe Éthique et Santé